Skip to content
OpenCapital
Get started

Dogwood Therapeutics DWTX Gain (Loss), Foreign Currency Transaction, before Tax

Gain (Loss), Foreign Currency Transaction, before Tax at other companies

Vertex Pharmaceuticals logo
Vertex PharmaceuticalsVRTX
——

Segments

By segment

See full
Single Reportable-$5.86K+74.8%

Other financials

Income statement

See full
Operating income-$5.1M-14.6%
Net income-$5.0M+54.4%
EPS (diluted)-$0.15+98.2%

Balance sheet

See full
Cash & equivalents$13.2M-24.6%
Total debt$144.9K-24.2%
Total equity$80.6M+1,038%
Total assets$95.2M-1.8%

Cash flow

See full
Operating cash flow-$4.6M+2.0%

Valuation

See full
Market cap$54.14M-57.6%
Enterprise value$41.06M-64.7%

Returns & leverage

See full
Return on equity-64.6%-29.8pp
Debt / equity0×0.0×
Current ratio5.9×-1.6×

Where this comes from

Reported directly by Dogwood Therapeutics in its filing.

Tagged under the XBRL concept us-gaap:ForeignCurrencyTransactionGainLossBeforeTax.

The official record: Dogwood Therapeutics’s 10-Q, filed May 15, 2026, on SEC EDGAR. View the filing →

Ask your AI about Dogwood Therapeutics's gain (loss), foreign currency transaction, before tax.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Dogwood Therapeutics's gain (loss), foreign currency transaction, before tax?
Dogwood Therapeutics (DWTX) reported gain (loss), foreign currency transaction, before tax of -$5.86K in Q1 2026.
How has Dogwood Therapeutics's gain (loss), foreign currency transaction, before tax changed year-over-year?
Dogwood Therapeutics's gain (loss), foreign currency transaction, before tax increased by 74.8% year-over-year, from -$23.27K to -$5.86K.